List of Excipients in Branded Drug AMJEVITA

Amjevita Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 8, 2026

Amjevita (adalimumab-atto) is Amgen’s U.S. biosimilar to AbbVie’s Humira (adalimumab). Its excipient strategy prioritizes protein stability, subcutaneous tolerability, manufacturability, and compatibility with prefilled syringes and autoinjectors. The largest commercial opportunities are not in commodity excipient supply alone. They are in low-volume biologic formulation development, device-compatible presentations, analytical comparability, and next-generation high-concentration or citrate-free adalimumab products.

Amjevita received U.S. Food and Drug Administration approval in 2016 and launched in the U.S. on January 31, 2023, following a patent-settlement agreement with AbbVie. It is not designated interchangeable with Humira under the FDA’s Purple Book. The product is not listed in the Orange Book because biologic products are tracked through the Purple Book rather than the Orange Book (FDA, 2016; FDA, 2024).

What excipients are used in Amjevita?

Amjevita uses a conventional liquid monoclonal-antibody formulation containing a phosphate buffer system, mannitol, polysorbate 80, and water for injection. The formulation is supplied in prefilled syringes and autoinjectors at a 40 mg/0.8 mL presentation, equivalent to a 50 mg/mL concentration. A 20 mg/0.4 mL presentation is available for selected pediatric dosing requirements.

Formulation element	Amjevita role	Commercial relevance
Adalimumab-atto	Active monoclonal antibody	Requires control of aggregation, degradation, potency, and immunogenicity
Sodium phosphate salts	Buffer system	Controls formulation pH and supports protein stability
Mannitol	Tonicity and stabilizing excipient	Supports osmolality and protein formulation performance
Polysorbate 80	Surfactant	Reduces surface adsorption and agitation-related aggregation
Water for injection	Vehicle	Must meet parenteral quality and bioburden requirements

The FDA prescribing information identifies mannitol, polysorbate 80, sodium phosphate salts, and water for injection as inactive ingredients in Amjevita. Exact excipient quantities and formulation specifications are controlled within the approved product dossier and manufacturing process (FDA, 2023a).

Why does Amjevita use polysorbate 80?

Polysorbate 80 protects the antibody from adsorption to glass, elastomeric components, manufacturing equipment, and container surfaces. It also reduces aggregation caused by shaking and interfacial stress during filling, transport, and injection.

The excipient creates its own quality-control burden. Polysorbate 80 can undergo hydrolysis and oxidation, producing degradation products that may affect protein stability and generate subvisible particles. Suppliers and manufacturers therefore need control strategies for:

• Peroxide and aldehyde impurities
• Fatty-acid composition
• Hydrolysis products
• Lot-to-lot variability
• Interaction with tungsten, stainless steel, glass, and elastomer components
• Long-term stability under refrigerated and room-temperature excursion conditions

This creates an opportunity for high-purity, low-peroxide polysorbate 80 and for analytical services that measure surfactant degradation in finished biologics.

Why is mannitol commercially important?

Mannitol helps adjust tonicity and can contribute to protein stabilization. It is widely available and generally has low unit value relative to the active ingredient. The commercial differentiation is therefore more likely to come from pharmaceutical-grade consistency, particle control, low endotoxin burden, and validated supply reliability than from the chemical identity of mannitol.

Mannitol can also affect crystallization, osmolality, viscosity, and freeze-thaw behavior. Suppliers that provide material specifically qualified for liquid monoclonal-antibody formulations can compete on regulatory documentation and performance data rather than price alone.

How does Amjevita’s formulation compare with Humira?

Amjevita is a biosimilar, not a generic chemical copy. Its formulation does not need to use the same excipients in the same quantities as Humira. The FDA evaluates whether the biosimilar is highly similar to the reference product and whether observed differences have no clinically meaningful effect on safety, purity, or potency.

Attribute	Amjevita	Humira
Active ingredient	Adalimumab-atto	Adalimumab
Sponsor	Amgen	AbbVie
FDA pathway	Biosimilar under section 351(k)	Original biologic under section 351(a)
Initial U.S. approval	2016	2002
U.S. launch	January 31, 2023	2002
Standard presentation	40 mg/0.8 mL	Multiple presentations, including 40 mg/0.8 mL and 40 mg/0.4 mL
Interchangeability	Not designated interchangeable	Reference product
Regulatory listing	Purple Book	Purple Book
Formulation flexibility	Must meet biosimilarity requirements	Originator formulation can be modified through supplemental approval

Humira later moved toward a 40 mg/0.4 mL high-concentration, citrate-free presentation. Amjevita’s commercial opportunity is constrained when prescribers and patients prefer a lower-volume injection. This creates a clear formulation-development opportunity for a higher-concentration Amjevita presentation or a follow-on product with reduced injection volume.

What formulation opportunities exist for Amjevita?

High-concentration adalimumab

A 100 mg/mL or similar high-concentration presentation could reduce injection volume from 0.8 mL to approximately 0.4 mL for a 40 mg dose. The technical challenges include:

• Higher protein concentration
• Increased viscosity
• Greater risk of aggregation
• More difficult syringeability
• Greater sensitivity to container closure and device components
• More demanding subvisible-particle control
• Potentially higher injection force

A successful formulation may require optimization of buffer concentration, pH, surfactant level, tonicity agent, protein concentration, and device geometry. The commercial value is significant because injection volume and injection discomfort influence patient and prescriber preference in chronic self-administered therapy.

Citrate-free and low-irritation formulations

Citrate-free formulations became commercially important in adalimumab because citrate-containing products were associated with injection-site discomfort concerns. Although Amjevita’s disclosed excipient system uses phosphate rather than citrate, a future differentiated product could emphasize reduced injection pain through a combination of:

• Citrate-free buffering
• Lower injection volume
• Lower injection force
• Optimized pH and osmolality
• Improved needle geometry
• Controlled surfactant concentration
• Autoinjector delivery

The commercial claim would need to be supported by clinical or human-factors evidence. Excipient substitution alone does not establish a superior patient experience.

Lyophilized or more stable presentations

Amjevita is supplied as a liquid formulation. A lyophilized adalimumab product could improve stability in selected distribution environments, but it would add reconstitution complexity and could reduce convenience for home injection. The strongest opportunity is more likely to be a liquid formulation with improved room-temperature stability rather than a conventional vial-based lyophilized product.

Device-compatible formulation design

The excipient system must be evaluated with:

• Glass syringes
• Silicone oil
• Needle shields
• Elastomeric plungers
• Autoinjector springs
• Lubricants
• Extractables and leachables
• Agitation during shipment

The formulation and device cannot be optimized independently. A surfactant level that protects the protein may interact with silicone oil or elastomeric components. A high-concentration formulation may require a different plunger force and injection time. Device compatibility is therefore a meaningful intellectual-property and development opportunity.

What patents protect Amjevita and adalimumab products?

Amjevita entered the U.S. under a settlement and license arrangement with AbbVie rather than through a final court determination invalidating the entire Humira patent estate. Amgen and AbbVie announced the settlement in 2017. The agreement permitted Amgen to commercialize Amjevita in the United States beginning January 31, 2023, subject to the settlement terms (Amgen, 2017; AbbVie, 2017).

Key patent categories affecting Amjevita include:

Patent category	Relevance to Amjevita
Adalimumab composition patents	Covered the original antibody and related claims; major early barriers largely expired or were overtaken by later patents
Formulation patents	Could cover concentration, buffer, surfactant, stabilizer, or liquid stability parameters
Manufacturing patents	Could cover cell culture, purification, viral clearance, or process conditions
Method-of-use patents	Could cover treatment of specific diseases, dosing regimens, or patient populations
Device and presentation patents	Could cover autoinjectors, syringes, needle systems, or container configurations
Settlement and license rights	Controlled the timing and conditions of Amjevita’s market entry

The key commercial point is that a biosimilar can launch after obtaining FDA approval but still face contractual or patent-related limits on launch timing, indications, or commercialization terms.

When did Humira lose U.S. exclusivity?

Humira’s FDA data exclusivity period ended in 2016, 12 years after its initial approval. That did not end patent protection. The product retained an extensive patent estate, including formulation, manufacturing, dosing, and method-of-use patents. Amjevita’s 2016 approval therefore preceded its 2023 commercial launch.

The principal U.S. composition patent, U.S. Patent No. 6,090,382, expired in 2023 after applicable adjustments and extensions. Later Humira patents extended commercial barriers for particular formulations, methods, and processes. Amgen’s launch timing reflected the AbbVie settlement rather than the expiration of every Humira-related patent.

What is the Orange Book and Purple Book status of Amjevita?

Amjevita is not an Orange Book product. The Orange Book primarily identifies approved small-molecule drugs, their therapeutic equivalence codes, and listed patents or exclusivity information. Amjevita is a licensed biological product and is recorded in the FDA Purple Book.

The Purple Book identifies:

• The reference product
• The biosimilar product
• Biosimilarity status
• Interchangeability status
• Exclusivity information relevant to biologics

Amjevita is biosimilar to Humira but is not listed as interchangeable. Pharmacies therefore generally cannot substitute it automatically under state substitution laws in the same way they may substitute an interchangeable biologic or therapeutically equivalent small-molecule generic.

What Paragraph IV challenges affected Amjevita?

Paragraph IV certification is a Hatch-Waxman mechanism for abbreviated new drug applications involving small-molecule drugs. It is not the standard approval mechanism for biosimilars. Amjevita proceeded through the Public Health Service Act’s section 351(k) biosimilar pathway.

The relevant biosimilar patent process is the patent dance under the Biologics Price Competition and Innovation Act. That process involves exchange of patent information, infringement claims, and potential litigation before commercial launch. Amgen and AbbVie engaged in litigation and negotiated settlement terms that established the Amjevita launch date.

The distinction matters for excipient companies. A formulation supplier working on a biosimilar biologic must assess patent risk around formulation and delivery claims, but it should not treat the project as a conventional Paragraph IV generic filing.

What commercial opportunities exist in Amjevita’s excipient supply chain?

Pharmaceutical-grade polysorbate 80

The strongest excipient opportunity is high-purity polysorbate 80 with documented control of oxidation, hydrolysis, fatty-acid profile, and particulate burden. Buyers increasingly value:

• Dual-source supply
• Change-control discipline
• Lot comparability
• Low-peroxide specifications
• Biologics-specific stability data
• Global regulatory support
• Reliable supply during capacity constraints

Buffer and tonicity systems

Sodium phosphate salts and mannitol are established materials. The opportunity is more limited for differentiated chemistry but remains relevant for:

• Compendial-grade supply
• Low-endotoxin grades
• Sterile or ready-to-use solutions
• Custom buffer concentrates
• Global registration support
• Consistent osmolality and pH performance

Excipient characterization and analytics

Analytical service providers can support:

• Polysorbate degradation profiling
• Protein aggregation analysis
• Subvisible and visible particle testing
• Extractables and leachables evaluation
• Container closure integrity
• Forced degradation studies
• Comparability protocols for formulation changes
• Stability modeling for temperature excursions

These services have higher margins than bulk excipient sales and are relevant across multiple adalimumab biosimilars.

Contract development and manufacturing

CDMOs can offer formulation screening, aseptic fill-finish, device assembly, and stability programs for:

• 40 mg/0.8 mL prefilled syringes
• Autoinjectors
• High-concentration presentations
• Pediatric strengths
• Regional packaging configurations
• Alternate storage and transport profiles

A supplier with experience in liquid monoclonal antibodies and combination products has a stronger position than a supplier limited to bulk excipient distribution.

How strong is the Amjevita patent estate?

Amjevita’s own product protection is less important than the surrounding adalimumab patent and regulatory framework. Its commercial defensibility depends on:

1. FDA biosimilar approval.
2. The AbbVie license and settlement.
3. Manufacturing know-how.
4. Product-specific analytical and process controls.
5. Device presentation and supply-chain execution.
6. Payer access and contracting.

The excipient formulation has limited standalone exclusivity unless supported by patent claims directed to specific concentrations, pH ranges, stability profiles, container systems, or delivery devices. Broad claims to common excipients such as mannitol, phosphate, and polysorbate 80 are generally difficult to use as durable differentiation without narrow technical limitations.

Which companies challenge Amjevita commercially?

Amjevita competes with Humira and multiple adalimumab biosimilars. U.S. competitors include products associated with companies such as Boehringer Ingelheim, Sandoz, Pfizer, Samsung Bioepis, Organon, Coherus, Celltrion, Fresenius Kabi, and Teva, depending on the specific product, launch timing, and market channel.

The competitive factors are:

• Wholesale acquisition cost
• Net price after rebates
• Interchangeability designation
• Formulary placement
• Patient support
• Autoinjector availability
• Injection volume
• Prescriber familiarity
• Specialty-pharmacy distribution
• Indication coverage
• Manufacturing reliability

Amjevita’s first-mover position did not guarantee market dominance. In adalimumab, commercial performance depends heavily on contracting and payer strategy because several biosimilars compete in the same therapeutic category.

What revenue exposure does Amjevita create?

Amjevita addresses a market formerly dominated by Humira, which generated approximately $21.2 billion in global revenue for AbbVie in 2022, its final full year before U.S. biosimilar competition began (AbbVie, 2023). AbbVie reported a sharp decline in Humira sales after U.S. biosimilar launches.

Amgen does not generally disclose Amjevita revenue as a separate standalone line in the same detail as the largest originator products. The revenue opportunity is therefore best assessed through:

• U.S. adalimumab market share
• Net price per syringe
• Rebate and discount levels
• Payer coverage
• Specialty-pharmacy volume
• International sales
• Cost of goods
• Device and fill-finish economics

For excipient suppliers, the addressable value is modest relative to adalimumab drug sales but recurring across the entire biosimilar class. A supplier that qualifies with one adalimumab manufacturer can potentially reuse the platform across other tumor necrosis factor biologics and monoclonal antibodies.

What generic launch risks exist for Amjevita?

Amjevita does not face conventional generic substitution risk because it is a biologic. Its principal risks are:

• Rapid price erosion from multiple biosimilars
• Loss of preferred formulary status
• Lack of automatic interchangeability
• Patient switching friction
• Manufacturing deviations
• Polysorbate or particle-related stability failures
• Device complaints
• Supply interruptions
• Patent disputes involving new presentations
• Competition from high-concentration and citrate-free products

The most durable product differentiation will likely come from a combination of formulation, device, patient support, and payer access rather than from the base excipient system alone.

Key Takeaways

• Amjevita is a 351(k) biosimilar to Humira, not a conventional generic.
• Its disclosed formulation uses sodium phosphate salts, mannitol, polysorbate 80, and water for injection.
• Polysorbate 80 quality, oxidation control, and container compatibility are the most important excipient supply-chain issues.
• Amjevita is recorded in the FDA Purple Book, not the Orange Book.
• It launched in the U.S. on January 31, 2023, under a settlement with AbbVie.
• Amjevita is not designated interchangeable with Humira.
• The clearest formulation opportunity is a higher-concentration, lower-volume, citrate-free or low-irritation presentation.
• Commodity mannitol and phosphate supply has limited differentiation; biologics-grade qualification and regulatory support create greater value.
• Excipient analytics, device compatibility, fill-finish, and stability services offer stronger commercial opportunities than bulk excipient sales.
• Humira’s patent estate created launch barriers beyond the expiration of the original composition patent.

FAQs

Is Amjevita citrate-free?

Amjevita’s disclosed excipient system uses sodium phosphate salts rather than citrate salts. Its commercial positioning should still be evaluated by presentation, injection volume, device design, and patient-experience data rather than by buffer identity alone.

Is Amjevita interchangeable with Humira?

No. Amjevita is FDA-approved as a biosimilar to Humira but does not have an interchangeable designation in the FDA Purple Book.

Does Amjevita contain polysorbate 80?

Yes. Polysorbate 80 is included as a surfactant to reduce protein adsorption and aggregation caused by interfaces and agitation.

Can a different excipient formulation be used for a future Amjevita product?

A modified formulation may be possible, but it would require FDA review supported by analytical comparability, stability, manufacturing, device, and clinical or pharmacologic evidence appropriate to the proposed change.

Which excipient is the best commercial opportunity in adalimumab biosimilars?

High-quality polysorbate 80 has the strongest direct opportunity because it is performance-sensitive in monoclonal-antibody formulations. Higher-value opportunities also exist in formulation development, degradation analytics, container compatibility, and device-integrated fill-finish.

References

1. AbbVie Inc. (2023). 2022 annual report. AbbVie.

2. Amgen Inc. (2017). Amgen and AbbVie reach global patent settlement for biosimilar adalimumab. Amgen.

3. Food and Drug Administration. (2016). FDA approves Amjevita, a biosimilar to Humira. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2023a). Amjevita (adalimumab-atto) prescribing information. U.S. Department of Health and Human Services.

5. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.